Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).

Davide Capodanno, Giuseppe Giacchi, Corrado Tamburino
{"title":"Current status and ongoing development of reversing agents for novel oral anticoagulants (NOACs).","authors":"Davide Capodanno,&nbsp;Giuseppe Giacchi,&nbsp;Corrado Tamburino","doi":"10.2174/15748901112079990013","DOIUrl":null,"url":null,"abstract":"<p><p>Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds. </p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":"8 1","pages":"2-9"},"PeriodicalIF":0.0000,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/15748901112079990013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation. Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are currently under investigation as reversing agents of NOACs. This article provides an overview of potential NOACs antidotes, including recent patents of emerging compounds.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型口服抗凝剂(NOACs)逆转剂的现状及发展趋势。
与维生素K拮抗剂相比,新型口服抗凝剂(NOACs)在高血栓栓塞潜力疾病(包括非瓣膜性心房颤动)患者中具有多重安全性益处。虽然这些药物有几个明显的优势,但它们受到缺乏经证实的解毒剂的限制,这在危及生命的出血情况下可能是一个主要问题。目前正在研究几种不同的药物和化合物作为noac的逆转剂。本文概述了潜在的NOACs解毒剂,包括新兴化合物的最新专利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. Patents and Heart Valve Surgery - III: Percutaneous Heart Valves. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy? Ticagrelor: a novel drug for an old problem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1